Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The study details page now returns a 403 Forbidden error, replacing the usual content. The Home link and page navigation are no longer available on this page, indicating access is blocked rather than a content update.
    Difference
    0.5%
    Check dated 2026-09-29T22:01:20.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Access to the study page now shows a 403 Forbidden error, replacing the usual study record content with a minimal error screen that includes a 403 message and a Home button. This indicates restricted access to the page rather than an update to the study details or related content.
    Difference
    18%
    Check dated 2026-09-22T23:06:17.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page now displays a new revision label, updating from v3.6.6 to v3.7.0. This appears to be a backend or UI version update and does not change any study content or functionality on the page.
    Difference
    0.0%
    Check dated 2026-09-15T20:56:31.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.6.5 to v3.6.6, indicating a new revision of the page. This reflects maintenance rather than substantive changes to the study information.
    Difference
    0.0%
    Check dated 2026-09-01T19:08:56.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    IPD sharing language was added, outlining access for researchers, conditions for data sharing, and how to request IPD via Vivli. It also references related privacy protections and public availability timelines.
    Difference
    0.4%
    Check dated 2026-08-25T20:19:18.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.4 to v3.6.5, indicating a minor patch to the page's metadata.
    Difference
    0.0%
    Check dated 2026-08-11T18:33:22.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.